Skip to content
Studies have shown that active fund managers routinely underperform the S&P500 index*
Home
Articles
WALL STREET X
Forecasts
Portfolios
Wall Street X
Articles
Forecasts
Portfolios
Search
Results for
{phrase}
(
{results_count}
of
{results_count_total}
)
Displaying
{results_count}
results of
{results_count_total}
Intellia Therapeutics, Inc. (NASDAQ: NTLA)
NTLA Stock Predictions and Ratings
WSX Rating:
STRONG BUY
WSX Forecast (1yr):
75.70%
Analyst Rating:
BUY
Analyst Forecast (1yr):
70.50%
NTLA Stock Analysis
NTLA
PE Ratio:
NTLA
PEG Ratio:
Not Available
NTLA
Forward EPS Growth (12 month):
0.00%
NTLA
PS Ratio:
22.1
NTLA
PSG Ratio:
0.2
NTLA
Forward Revenue Growth (12 month):
94.50%
NTLA Articles
No data was found